Girardi P1, Rapinesi C, Chiarotti F, Kotzalidis GD, Piacentino D, Serata D, Del Casale A, Scatena P, Mascioli F, Raccah RN, Brugnoli R, Digiacomantonio V,Ferri VR, Ferracuti S, Zangen A, Angeletti G. ...Read More
This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. BrainsWay D treatment is FDA cleared for patients with MDD who failed to respond to one or more anti-depressants in the current episode.
Bersani, F. S., Minichino, A., Enticott, P. G., Mazzarini, L., Khan, N., Antonacci, G., & Biondi, M. (2013). European Psychiatry, 28(1), 30-39.
This paper reviews the work done so far using the Brainsway® Deep TMS (Deep Transcranial Magnetic Stimulation) H-coil, and demonstrates the biological and physical components that participate in the effects generated by Deep Transcranial Magnetic Stimulation; both in general terms and for specific psychiatry disorders.